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Stability of erythropoietin (EPO) depends on its 
glycosylation states. With more glycosylation sites, the EPO 
protein will be more stable and also increase its half-life. A 
construct of recombinant human erythropoietin (rhEPO) which 
contains 2 additional N-link for glycosylation were designed. Based 
on translation analysis using ORF (open reading frame)-finder and 
protein alignment analysis using blast-p of NCBI home page, 
expected recombinant hEPO with additional 6-histidin tag in 
carboxyl terminus was expressed. HEK293T cells were transfected 
with recombinant plasmid containing rhEPO by using calcium 
phosphate method. Expression of rhEPO was detected by dot blot 
and Western blot analysis using hEPO antibody as the primary 
antibody and antirabbit antibody with alkaline phospatase linked 
as the secondary antibody. The bands were detected by 
BCIP/NBT color development substrate. The data indicated 
detection of EPO in culture medium of transfected HEK293T cells.  
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INTRODUCTION 
Erythropoietin (EPO) is a glycoprotein 
which is very fundamental for red blood cells 
maturation (Ashley et al., 2002; Durocher and 
Butler, 2009; Egrie and Browne, 2009). Clinical 
therapy using EPO, especially recombinant 
human EPO (rhEPO), is very crucial for the 
treatment of anemia in the case of chronic renal 
failure patients (Goldwasser, 1975; Helena et al., 
2006). EPO consist of 165 amino acids with 
molecular weight of about 30 kDa. EPO 
synthesis needs post transcriptional 
modification for the addition of four 
carbohydrate chains by glycosylation at N and 
O sites. Glycosylation of human EPO is 
modified with addition of sialil groups which 
are important for in vivo stability (Egrie and 
Browne, 2001; Koury and Bondurant, 1991). So 
far synthesis or rhEPO for human therapeutic 
use is produced in mammalian cell, mainly in 
chinese hamster ovary (CHO) cells.  
Recently there are at least three kinds of 
rhEPO available in the market: epoietin alpha, 
epoietin beta, and darbopoietin alpha. Those 
rhEPO are produced by using Chinese hamster 
ovary (CHO) cells (Lotscher, 2005).  Besides 
mammalian system, another expression system 
frequently used is a prokaryotic system using 
bacteria. However, since prokaryotic system 
does not have post-translational modification 
capacity, thus, glycosylation moety can not be 
performed in this expression system (Fischer et 
al., 1999). Recently, the use of yeast as an 
eukaryotic expression system has gained a lot of 
attention. Like other eukaryotic systems, yeast 
can also perfom post-translational modification 
including synthesis of glycosylation (Cereghino 
and Cregg, 2000).  However, several studies 
have proven that the glycosylation pattern of 
yeast is very different than that of mammalian 
system (Dasgupta et al., 2007; Durocher and 
Butler, 2009; Lam et al., 2007; Moore, 2003). 
With regard to this, in this current study, we are 
interested to synthesize rhEPO using 
mammalian system.  
With the long-term goal of producing 
biosimilar product, we designed a construct of 
recombinant human erythropoietin (rhEPO) 
which contains 2 additional N-link  
glycosylation (Narhi et al., 1991). Study on 
rhEPO demonstrated that increase in sialic acid 
containing carbohydrate molecule increases its 
serum half-life and in vivo biological activity. To 
enable easy rapid purification of an expressed 
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protein product, the coding sequence of this 
therapeutically important human glycoprotein 
EPO was fused with a polyhistidine tag.  In this 
research, the modified glycosylation rhEPO 
was expressed in HEK 293T cells.  
 
METHODOLOGY 
Cell culture and reagents 
Human embryonic kidney HEK293T 
(293T) cells were obtained from Prof.            
Masashi Kawaichi, Nara Institute of             
Science and Technology (NAIST), Japan. Cells 
were cultured in DMEM medium (Sigma) 
supplemented with 10% of fetal bovine            
serum (FBS, Gibco) and 1% of mixture of 
antibiotics (penicillin-streptomycin, Gibco). 
Plasmid construct pJ-601 which contains 
optimized rhEPO sequence (pJ-rhEPO) was            
obtained from DNA 2.0, USA. This rhEPO 
sequence was expected to express 5-N-link 
rhEPO with 6x histidin tag at C-terminus. 
Plasmid pEGFP-c1 was from Prof. Masashi             
Kawaichi.    
 
Calcium phosphate transfection 
One day before transfection, 2x104 
cells/well were seeded on to 24 well plates. 
Before transfection, culture medium was 
changed with 450 uL fresh medium. 
Transfection reagents were made as follows: 4 
tubes of 100 uL of 0.25M of CaCl2 were added 
with 0.4 ug and 0.8 ug pEGFP-c1, 0.7 ug and 1 
ug pJ-EPO respectively. Then, 100 ul of BBS 
reagent pH 6.95 were added drop by drop with 
shaking into CaCl2-DNA mixture and 
incubated for 20 minutes at room temperature. 
After incubation, 50ul of each mixture were 
added in to cell culture in each well and mixed 
properly and then incubated over night.               
The next day, GFP fluorescence was observed 
using inverted fluorescent microscope to 
confirm the transfection method worked            
well. The cells medium then were changed  with 
fresh medium every day which contain 




The fourth day after transfection, cells 
were splitted into 24 well plate and incubated 
for 2 days to check the presence of rhEPO in 
culture medium by dot blotting. Ten uL of 
culture medium were spotted into nitrocellulose 
membrane in laminar air flow hood and let to 
dry. The membrane was then soaked into 
blocking solution (5% skimmed milk in TBS) 
and incubated with shaking for 1 hour then was 
washed thrice with 0.1% tween in TBS             
(TBS-T). The membrane was incubated with 
primary anti-EPO antibody (1:1000) 
(Calbiochem) in blocking solution for 1 hour. 
Following TBS-T washing, the membrane            
was incubated with secondary antirabbit 
antibody (1:10,000) (Promega) in blocking 
solution for 1 hour. After washing, the 
membrane was stained with NBT-BCIP 
(Promega) in AP-buffer for 10 minutes and 
then washed with water.        
 
Western blotting 
The fourth day after transfection, cells 
were splitted into 24 well plate and incubated 
for four days to check the presence of rhEPO 
in culture medium by western blotting. 15µl of 
culture medium was added with 5µl of 5× SDS 
buffer and then boiled for 5 minutes. Epoetin-
alpha (Hemapo) as positive control of 3 N-
linked rhEPO was from Kalbe Farma. After 
running of SDS PAGE, polyacrylamide gel 
then was blotted on to nitrocellulose 
membrane. The membrane then was soaked 
into blocking solution (5% skimmed milk in 
TBS) and incubated with shaking for 1 hour 
then was washed thrice with 0.1% tween in 
TBS (TBS-T). Next, the membrane was 
incubated with primary anti-EPO antibody 
(1:1,000) (Calbiochem) in blocking solution for 
1 hour. Following TBS-T washing, the 
membrane was incubated with secondary 
antirabbit antibody (1:10,000) (Promega) in 
blocking solution for 1 hour. After washing, the 
membrane was stained with NBT-BCIP 
(Promega) in AP-buffer for 10 minutes and 
then washed with water. 
 
RESULTS AND DISCUSSION 
Containing 2 additional N-links, 
recombinant plasmid pJ-EPO was designed to 
enhance in vivo stability of expressed rh-EPO. 
Analysis of the recombinant plasmid was 
carried out by using restriction enzyme 
digestion of pJ-EPO plasmid (Figure 1).          
The small fragment which is shown after 
digestion   refers  to  the  fragment of interest.   
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Figure 2.  Digestion of pJ-EPO by using 
restriction enzyme MluI and XhoI. 1) DNA 
ladder, 2) MluI/XhoI digested pJ-EPO, 3) pJ-
EPO 0,5ug, 4) pJ-EPO 1ug. White arrow 
showed insert fragment around 500 bp. 
The result showed that digestion of pJ-EPO 
using MluI/XhoI resulted in the presence of 
approximately 500 bp EPO insert (Figure 2). 
 
Efficiency of transfection depends on 
the amount of plasmid DNA used, number of 
cells, and time of incubation (Sola and 
Griebenow, 2009). Confirmation of calcium 
phosphate transfection method was performed 
using pEGFP-c1 plasmid. With the presence of 
gfp gene in the pEGFP-c1 plasmid, the 
transfected 293T cells express green 
fluorescence protein (GFP) and the  GFP was  
detected using fluorescent microscope.  With 
the use of 0.4 µg of pEGFP-c1 plasmid, green 
fluorescence was observed 12 hours after 
transfection (Figure 3). 
Transfection of HEK293T cells with pJ-
EPO was also done by calcium phosphate 
method. One day after transfection, cells were 
incubated with G418 for selection of successful 
transformants. The next day, cells were passed 
and grown in new 24 well plate. The remaining 
cells were grown until 100% confluency. The 
culture medium was then analyzed by dot blot 
and western blot. Dot blot data indicated 
detectable EPO protein in different expression 
level (Figure 4).  
To clarify the detected EPO, SDS 
PAGE and Western blotting were performed. 
Epoietin alpha and rhEPO from previous 
experiment produced in Pichia pastoris were used 
as positive controls. Epoetin alpha possesses 
molecular weight of about 30 kDa. However, 
the band of epoietin alpha appeared around 35 
kDa (Yoon et al., 2001). As a comparison, 
rhEPO of Pichia pastoris has the molecular 
weight of about 35 kDa. The increased size of 
rhEPO of Pichia pastoris is due to the presence 
of fused c-myc and histag at the carboxy 
terminus of the protein. The band of this 
rhEPO appeared around 35 kDa (Wardiana 
and Santoso, 2011). Moreover, the Western 
blot data showed that the EPO protein was 
expressed in all four culture medium.  In clone 
1, a single band with the approximate size of 50 
kDa was detected.  The two additional N-
linked glycosylations of rhEPO contribute to 
the addition of molecular mass of the protein 
approximately 6.6 kDa. While 6-histidin tag 
increase the molecular weight of the protein of 
about 1 kDa. The expected rhEPO which 
possesses 5 N-linked glycosylation appeared 
around 50 kDa (Figure 5). The results shown 
resemble to the detected rhEPO with 5 N-
linked glycosylation state which appeared 
around 50 kDa (Gross and Lodish, 2006). The 
bands appeared around 35 kDa seemed to be 
EPO and its isoforms (Sola and Griebenow, 
2010). Eventhough the detected EPO was 
expected to be rhEPO, further experiments are 
needed to purify and characterize the rhEPO to 
confirm additional N-link for glycosylation site. 
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Based on our translational analysis using 
ORF (open reading frame)-finder and protein 
alignment analysis using blast-p of NCBI home 
page, pJ-EPO would express expected rhEPO 
with additional 6-histidin tag in carboxyl 
terminus. rhEPO with modification of its 
amino acid would performed additional N-link 
glycosylation in post transcription modification. 
With more glycosylation sites, the EPO protein 
expected to be more stable and also increase its 
half-life (Jordan et al., 1996; Bollin et al., 2011). 
Suspension culture generally use for 
production of recombinant protein to obtain 
high yields (Mariati et al., 2010). In this 
experiment, culture of adherent cells was used 
for    detection   of   EPO.   For   further  EPO  
 
Figure 3. Transfection of HEK293T with pEGFP-c1 by using calcium 
phosphate method. The transfected cells show green fluorescence 
observed under fluorescence microscope. 
 
 
Figure 4. Dot blot analysis of culture 
medium in 24 well plate after cells 
selection with G418 showed different 
detection level of rhEPO.  
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production, suspension culture will be use to 
increase the yields. Transfection can be done by 
using transient or stable transfection methods 
(Suzuki et al., 2006; Backliwal et al., 2008). 
Transient transfection is not time consuming 
but it shows low productivity (Loignon et al., 
2008). However, experiments are set up to 
develop rapid methods to gain stable 
transformants to enhance productivity 
(Strickland, 1999; Pattel, 2009). 
 
CONCLUSION 
Dot blot and Western blot data indicated 
detection of EPO in culture medium of  
transfected 293T cells.  
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